Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Hydrocodone | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Magnesium sulfate | The therapeutic efficacy of Brilaroxazine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Brilaroxazine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Mirtazapine | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Orphenadrine | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Pramipexole | Brilaroxazine may increase the sedative activities of Pramipexole. |
| Ropinirole | Brilaroxazine may increase the sedative activities of Ropinirole. |
| Rotigotine | Brilaroxazine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Brilaroxazine. |
| Sodium oxybate | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Thalidomide | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Brilaroxazine may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Brilaroxazine. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Brilaroxazine. |
| Sulpiride | Brilaroxazine may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Brilaroxazine. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Brilaroxazine. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Brilaroxazine. |
| Mequitazine | Brilaroxazine may increase the arrhythmogenic activities of Mequitazine. |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Deutetrabenazine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with (S)-Warfarin. |
| Ethanol | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Brilaroxazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Brilaroxazine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Brilaroxazine. |
| Indalpine | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Brilaroxazine is combined with Alaproclate. |
| Carbidopa | The therapeutic efficacy of Carbidopa can be decreased when used in combination with Brilaroxazine. |
| Benzatropine | The therapeutic efficacy of Benzatropine can be decreased when used in combination with Brilaroxazine. |
| Cabergoline | The therapeutic efficacy of Cabergoline can be decreased when used in combination with Brilaroxazine. |
| Tolcapone | The therapeutic efficacy of Tolcapone can be decreased when used in combination with Brilaroxazine. |
| Metixene | The therapeutic efficacy of Metixene can be decreased when used in combination with Brilaroxazine. |
| Trihexyphenidyl | The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Brilaroxazine. |
| Procyclidine | The therapeutic efficacy of Procyclidine can be decreased when used in combination with Brilaroxazine. |
| Profenamine | The therapeutic efficacy of Profenamine can be decreased when used in combination with Brilaroxazine. |
| Entacapone | The therapeutic efficacy of Entacapone can be decreased when used in combination with Brilaroxazine. |
| Lisuride | The therapeutic efficacy of Lisuride can be decreased when used in combination with Brilaroxazine. |
| Apomorphine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Brilaroxazine. |
| Biperiden | The therapeutic efficacy of Biperiden can be decreased when used in combination with Brilaroxazine. |
| Amantadine | The therapeutic efficacy of Amantadine can be decreased when used in combination with Brilaroxazine. |
| Memantine | The therapeutic efficacy of Memantine can be decreased when used in combination with Brilaroxazine. |
| Pergolide | The therapeutic efficacy of Pergolide can be decreased when used in combination with Brilaroxazine. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Brilaroxazine. |
| Levodopa | The therapeutic efficacy of Levodopa can be decreased when used in combination with Brilaroxazine. |
| Rasagiline | The therapeutic efficacy of Rasagiline can be decreased when used in combination with Brilaroxazine. |
| 3,5-Dinitrocatechol | The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Brilaroxazine. |
| Etilevodopa | The therapeutic efficacy of Etilevodopa can be decreased when used in combination with Brilaroxazine. |
| Safinamide | The therapeutic efficacy of Safinamide can be decreased when used in combination with Brilaroxazine. |
| Ifenprodil | The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Brilaroxazine. |
| Dexetimide | The therapeutic efficacy of Dexetimide can be decreased when used in combination with Brilaroxazine. |
| Opicapone | The therapeutic efficacy of Opicapone can be decreased when used in combination with Brilaroxazine. |
| Piribedil | The therapeutic efficacy of Piribedil can be decreased when used in combination with Brilaroxazine. |
| Benserazide | The therapeutic efficacy of Benserazide can be decreased when used in combination with Brilaroxazine. |
| Tropatepine | The therapeutic efficacy of Tropatepine can be decreased when used in combination with Brilaroxazine. |
| Melevodopa | The therapeutic efficacy of Melevodopa can be decreased when used in combination with Brilaroxazine. |
| Dihydroergocryptine | The therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Brilaroxazine. |